| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Benjamin Rossi maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $2...
Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from ...
Health insurer stocks fell after the Senate ended the shutdown without extending ACA subsidies, delaying the decision to Decemb...
Truist Securities analyst David Macdonald reiterates Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from...
RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:THC) with a Outperform and raises the price target from $23...
UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $238 to $260.
Cantor Fitzgerald analyst Sarah James maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target fr...